Menée en Espagne auprès de 151 patients atteints d'un cancer traité par chimiothérapie, cette étude observationnelle analyse les altérations auto-rapportées du goût et de l'odorat, en fonction du type d'agents chimiothérapeutiques reçus (anthracyclines, sels de platine, paclitaxel, docétaxel, etc.)

Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatment

Amézaga, Javier ; Alfaro, Begoña ; Ríos, Yolanda ; Larraioz, Aitziber ; Ugartemendia, Gurutze ; Urruticoechea, Ander ; Tueros, Itziar

Purpose : Taste and smell changes are common side effects in cancer patients undergoing chemotherapy treatments (CT). This can lead to a reduced food enjoyment and an inadequate nutrient intake with a high impact on nutritional status and quality of life. The aim of this study was to evaluate the self-reported chemosensory alterations of patients undergoing chemotherapy according to CT type. Methods : An observational study was conducted with 151 patients undergoing CT at Oncology Outpatient [...]

A partir de données portant sur 365 patients adultes ayant survécu à une leucémie lymphoblastique aiguë pendant l'enfance et sur 365 témoins, cette étude évalue l'association entre une neuropathie périphérique, des troubles de l'équilibre statique, la mobilité, l'endurance pendant la marche et la qualité de vie

Peripheral Neuropathy, Sensory Processing, and Balance in Survivors of Acute Lymphoblastic Leukemia

Mitra Varedi ; Lu Lu ; Carrie R. Howell ; Robyn E. Partin ; Melissa M. Hudson ; Ching-Hon Pui ; Kevin R. Krull ; Leslie L. Robison ; Kirsten K. Ness ; Raymond F. McKenna

Purpose : To compare peripheral nervous system function and balance between adult survivors of childhood acute lymphoblastic leukemia (ALL) and matched controls and to determine associations between peripheral neuropathy (PN) and limitations in static balance, mobility, walking endurance, and quality of life (QoL) among survivors. Patients and Methods : Three hundred sixty-five adult survivors of childhood ALL and 365 controls with no cancer history completed assessments of PN (modified Total [...]

Menée en France à partir de données portant sur 524 patientes atteintes d'un cancer du sein de stade précoce, cette étude rétrospective analyse le risque de neutropénie fébrile induite par une chimiothérapie adjuvante ou néoadjuvante, puis évalue sa prise en charge

Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution

Bacrie, Joy ; Laurans, Marc ; Iorio, Pauline ; Fourme, Emmanuelle ; Volters, Anne Béthune ; Bozec, Laurence ; Lerebours, Florence ; Dubot, Coraline ; Bensaoula, Okba ; Benzidane, Bilel ; Pierga, Jean-Yves ; Lefeuvre, Delphine

Background : Febrile neutropenia (FN) is one of the most common and most critical adverse effects of chemotherapy. Despite many existing guidelines based on the use of granulocyte-colony stimulating factor (G-CSF), FN continues to impair the quality of life and interfere with the treatment of many patients. The purpose of this study was to assess the incidence and management of FN associated with chemotherapy for early breast cancer in routine clinical practice. Methods : All patients with [...]

Menée aux Etats-Unis à partir de données portant sur 2 317 185 patients ayant survécu à une tumeur solide (âge médian : 63 ans), cette étude analyse l'association entre la période de suivi des programmes de soins dédiés à l'après-cancer et la mortalité, selon le type de cancer, et met en évidence l'inadéquation de la durée de surveillance standard de 5 ans avec certains types de cancers

Defining survivorship trajectories across patients with solid tumors: An evidence-based approach

Dood, R. L. ; Zhao, Y. ; Armbruster, S. D. ; et al.,

Importance : Survivorship involves a multidisciplinary approach to surveillance and management of comorbidities and secondary cancers, overseen by oncologists, surgeons, and primary care physicians. Optimal timing and coordination of care, however, is unclear and often based on arbitrary 5-year cutoffs. Objective : To determine high- and low-risk periods for all tumor types that could define when survivorship care might best be overseen by oncologists and when to transition to primary care [...]

A partir des données de 195 pays, cette étude analyse l'évolution des disparités géographiques dans l'incidence de 29 types de cancers, dans la mortalité, dans les années de vies perdues et dans les années de vies perdues ajustées sur l'incapacité, sur la période 1990-2016

Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study

Global Burden of Disease Cancer, Collaboration

Importance : The increasing burden due to cancer and other noncommunicable diseases poses a threat to human development, which has resulted in global political commitments reflected in the Sustainable Development Goals as well as the World Health Organization (WHO) Global Action Plan on Non-Communicable Diseases. To determine if these commitments have resulted in improved cancer control, quantitative assessments of the cancer burden are required. Objective : To assess the burden for 29 cancer [...]

Menée aux Etats-Unis à partir de données portant sur 2 959 patients ayant survécu à un cancer, cette étude prospective analyse les facteurs associés au risque de septicémie

A prospective study of cancer survivors and risk of sepsis within the REGARDS cohort

Moore, Justin Xavier ; Akinyemiju, Tomi ; Bartolucci, Alfred ; Wang, Henry E. ; Waterbor, John ; Griffin, Russell

Background : Hospitalized cancer patients are nearly 10 times more likely to develop sepsis when compared to patients with no cancer history. We compared the risk of sepsis between cancer survivors and no cancer history participants, and examined whether race was an effect modifier. Methods : We performed a prospective analysis of data from the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. We categorized participants as “cancer survivors” or “no cancer history” [...]

Menée aux Etats-Unis et au Canada à partir de données portant sur 15 450 patients adultes ayant survécu à un cancer diagnostiqué avant l'âge de 21 ans entre 1970 et 1999 (âge médian lors de l'étude : 25,9 ans), cette étude de cohorte évalue l'association entre une activité physique d'intensité vigoureuse et la mortalité (durée médiane de suivi : 9,6 ans)

Association of exercise with mortality in adult survivors of childhood cancer

Scott, J. M. ; Li, N. ; Liu, Q. ; et al.,

Importance  : Adult survivors of childhood cancer are at excess risk for mortality compared with the general population. Whether exercise attenuates this risk is not known. Objective : To examine the association between vigorous exercise and change in exercise with mortality in adult survivors of childhood cancer. Design, Setting, and Participants : Multicenter cohort analysis among 15 450 adult cancer survivors diagnosed before age 21 years from pediatric tertiary hospitals in the United [...]

Menée aux Etats-Unis à partir de données portant sur la période 1976-2014, cette étude analyse l'évolution de l'incidence de cancer de l'ovaire, de la survie et de la mortalité spécifique, présente des projections pour l'année 2018, puis propose des pistes de réflexion pour améliorer la prévention et la détection précoce de la maladie

Ovarian cancer statistics, 2018

Torre Lindsey A. ; Trabert Britton ; DeSantis Carol E. ; Miller Kimberly D. ; Samimi Goli ; Runowicz Carolyn D. ; Gaudet Mia M. ; Jemal Ahmedin ; Siegel Rebecca L.

In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States. Herein, the American Cancer Society provides an overview of ovarian cancer occurrence based on incidence data from nationwide population‐based cancer registries and mortality data from the National Center for Health Statistics. The status of early detection strategies is also reviewed. In the United States, the overall ovarian cancer incidence rate declined [...]

Menée au Royaume-Uni à partir de données portant sur 722 patients atteints d'un cancer de la vessie sans envahissement musculaire, cette étude de cohorte prospective évalue l'association entre la cessation tabagique, avant et après le diagnostic de la maladie, et le risque de récidive (durée médiane de suivi : 4,21 ans)

The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study

van Osch, Frits H. M. ; Jochems, Sylvia H. J. ; Reulen, Raoul C. ; Pirrie, Sarah J. ; Nekeman, Duncan ; Wesselius, Anke ; James, Nicholas D. ; Wallace, D. Michael A. ; Cheng, K. K. ; van Schooten, Frederik J. ; Bryan, Richard T. ; Zeegers, Maurice P.

Background : Smoking is a major risk factor for bladder cancer, but the relationship between smoking cessation after initial treatment and bladder cancer recurrence has been investigated less frequently and not prospectively yet. Methods : 722 non-muscle-invasive bladder cancer (NMIBC) patients (pTa, pT1, and CIS) from the prospective Bladder Cancer Prognosis Programme (BCPP) cohort, selected in the UK between 2005 and 2011, provided complete data on smoking behavior before and up to 5 years [...]

Menée aux Etats-Unis auprès de 153 patients adolescents et jeunes adultes ayant survécu à un cancer, cette étude analyse l'association entre l'inquiétude liée à la maladie et la croissance post-traumatique

The Relationship Between Cancer-Related Worry and Posttraumatic Growth in Adolescent and Young Adult Cancer Survivors

McDonnell Glynnis A. ; Pope Alice W. ; Schuler Tammy A. ; Ford Jennifer S.

Objectives : To examine cancer‐related worry in adolescent and young adult (AYA) cancer survivors and its relationship with posttraumatic growth over time, as the relationship between these constructs has not been assessed longitudinally in this population. Methods : 153 AYA cancer survivors completed measures of cancer‐related worry and posttraumatic growth three times across approximately one year. Descriptive statistics were calculated for cancer‐related worry items, and mixed‐effects [...]

Menée en Australie auprès de 274 patients atteints d'un cancer du poumon récemment diagnostiqué, cette étude analyse l'association entre leurs perceptions d'une discrimination, ou d'une stigmatisation, et leurs comportements de recherche d'information et d'aide auprès des professionnels de santé

Help-seeking behaviour in newly diagnosed lung cancer patients: assessing the role of perceived stigma

Rose Shiho ; Boyes Allison ; Kelly Brian ; Cox Martine ; Palazzi Kerrin ; Paul Christine

Objective : This study explored help‐seeking behaviours, group identification and perceived legitimacy of discrimination, and its potential relationship with perceived lung cancer stigma. Methods : Consecutive consenting adults (n=274) with a primary diagnosis of lung cancer within the previous four months were recruited at 31 outpatient clinics in Australia. A self‐report survey assessed help‐seeking, group identification, perceived legitimacy of discrimination and perceived lung cancer [...]

Menée en Australie auprès de 408 patientes atteintes d'un cancer du sein devant être traité par radiothérapie, cette étude analyse l'intérêt d'une intervention pédagogique dirigée par un radiothérapeute pour diminuer la détresse psychologique des patientes et améliorer leurs connaissances relatives à la radiothérapie

RT Prepare: a radiation therapist-delivered intervention reduces psychological distress in women with breast cancer referred for radiotherapy

Halkett, Georgia ; O’Connor, Moira ; Jefford, Michael ; Aranda, Sanchia ; Merchant, Susan ; Spry, Nigel ; Kane, Robert ; Shaw, Thèrése ; Youens, David ; Moorin, Rachael ; Schofield, Penelope

Background : The aims of this study were to determine whether a radiation therapist-led patient education intervention (RT Prepare) reduced breasts cancer patients’ psychological distress (primary endpoint); anxiety, depression and concerns about radiotherapy, and increased knowledge of radiotherapy and preparedness (secondary endpoints). Patient health system usage and costs were also assessed. Methods : A multiple-baseline study across three sites. The RT Prepare intervention comprised two [...]

Cette étude passe en revue les essais cliniques en oncologie pédiatrique ainsi que les études portant sur les coûts associés à la recherche et développement, puis propose une stratégie financière et commerciale pour inciter les compagnies pharmaceutiques à accélérer le développement de produits thérapeutiques en oncologie pédiatrique

New business models to accelerate innovation in pediatric oncology therapeutics: A review

Das, S. ; Rousseau, R. ; Adamson, P. C. ; Lo, A. W.

Importance: Few patient populations are as helpless and in need of advocacy as children with cancer. Pharmaceutical companies have historically faced significant financial disincentives to pursue pediatric oncology therapeutics, including low incidence, high costs of conducting pediatric trials, and a lack of funding for early-stage research. Observations: Review of published studies of pediatric oncology research and the cost of drug development, as well as clinical trials of pediatric [...]

Menée dans un contexte américain et brésilien, cette étude analyse le rapport coût-efficacité de l'osimertinib en traitement de première ligne chez des patients atteints d'un cancer du poumon non à petites cellules présentant des mutations du gène EGFR et de stade avancé

Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non–small cell lung cancer

Aguiar, P. N. Jr, ; Haaland, B. ; Park, W. ; San Tan, P. ; del Giglio, A. ; de Lima Lopes, G.

Importance : The survival of patients with advanced non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the last decade with the development of targeted tyrosine kinase inhibitors (TKIs). Osimertinib, a third-generation TKI that is approved by the US Food and Drug Administration for the treatment of patients who develop EGFR T790M mutations, has recently shown improved clinical outcomes compared with gefitinib and [...]